DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
38 hedge funds and large institutions have $3.37M invested in DMK Pharmaceuticals Corporation Common Stock in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 18 closing their positions.
2,875% more call options, than puts
Call options by funds: $238K | Put options by funds: $8K
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
24% less funds holding
Funds holding: 50 → 38 (-12)
37% less capital invested
Capital invested by funds: $5.35M → $3.37M (-$1.98M)
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$350K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$203K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$19.5K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$12.1K |
| 5 |
Jane Street
New York
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$1.37M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$622K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$127K |
| 4 |
Morgan Stanley
New York
|
-$68.5K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$61K |
DMK Hedge Fund Activity: Q4 2019 in Review
38 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2019, worth a combined $3.37M — down 37% from $5.35M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of DMK and 6 opened new positions — a net loss of 12 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was BlackRock, adding an estimated $350K. The largest seller was 683 Capital Management, exiting entirely with an estimated $1.37M sold.
- 38 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2019, down from 50 in Q3 2019.
- Funds reported $3.37M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2019, down 37% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2019 and 18 closed out, a net change of -12 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2019 was BlackRock, an estimated $350K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2019 was 683 Capital Management, an estimated $1.37M sold.
Based on aggregated 13F filings for Q4 2019.